nodes	percent_of_prediction	percent_of_DWPC	metapath
Etodolac—PTGS2—colon cancer	0.395	1	CbGaD
Etodolac—UGT1A9—Irinotecan—colon cancer	0.156	0.417	CbGbCtD
Etodolac—ALB—Irinotecan—colon cancer	0.0485	0.129	CbGbCtD
Etodolac—ALB—Fluorouracil—colon cancer	0.0465	0.124	CbGbCtD
Etodolac—CYP2C9—Capecitabine—colon cancer	0.0423	0.113	CbGbCtD
Etodolac—SLC22A6—Methotrexate—colon cancer	0.0301	0.0804	CbGbCtD
Etodolac—ALB—Methotrexate—colon cancer	0.0257	0.0685	CbGbCtD
Etodolac—CYP2C9—Fluorouracil—colon cancer	0.0251	0.067	CbGbCtD
Etodolac—UGT1A10—renal system—colon cancer	0.00461	0.0929	CbGeAlD
Etodolac—UGT1A10—digestive system—colon cancer	0.00378	0.0762	CbGeAlD
Etodolac—UGT1A10—liver—colon cancer	0.00282	0.0567	CbGeAlD
Etodolac—RXRA—renal system—colon cancer	0.00275	0.0554	CbGeAlD
Etodolac—UGT1A3—digestive system—colon cancer	0.00266	0.0537	CbGeAlD
Etodolac—UGT1A9—renal system—colon cancer	0.00231	0.0466	CbGeAlD
Etodolac—ALB—gall bladder—colon cancer	0.00223	0.0448	CbGeAlD
Etodolac—UGT1A3—liver—colon cancer	0.00199	0.04	CbGeAlD
Etodolac—UGT1A9—digestive system—colon cancer	0.0019	0.0382	CbGeAlD
Etodolac—UGT2B7—renal system—colon cancer	0.00187	0.0376	CbGeAlD
Etodolac—RXRA—liver—colon cancer	0.00168	0.0338	CbGeAlD
Etodolac—UGT2B7—digestive system—colon cancer	0.00153	0.0308	CbGeAlD
Etodolac—PTGS1—endothelium—colon cancer	0.00146	0.0294	CbGeAlD
Etodolac—UGT1A9—liver—colon cancer	0.00141	0.0285	CbGeAlD
Etodolac—PTGS2—endothelium—colon cancer	0.0014	0.0281	CbGeAlD
Etodolac—PTGS1—blood vessel—colon cancer	0.00135	0.0272	CbGeAlD
Etodolac—PTGS2—blood vessel—colon cancer	0.00129	0.026	CbGeAlD
Etodolac—PTGS2—gall bladder—colon cancer	0.00121	0.0244	CbGeAlD
Etodolac—UGT2B7—liver—colon cancer	0.00114	0.023	CbGeAlD
Etodolac—PTGS2—embryo—colon cancer	0.000769	0.0155	CbGeAlD
Etodolac—PTGS1—epithelium—colon cancer	0.000656	0.0132	CbGeAlD
Etodolac—ALB—liver—colon cancer	0.000653	0.0131	CbGeAlD
Etodolac—PTGS1—smooth muscle tissue—colon cancer	0.000632	0.0127	CbGeAlD
Etodolac—PTGS2—epithelium—colon cancer	0.000627	0.0126	CbGeAlD
Etodolac—PTGS1—renal system—colon cancer	0.000609	0.0123	CbGeAlD
Etodolac—PTGS2—smooth muscle tissue—colon cancer	0.000604	0.0122	CbGeAlD
Etodolac—PTGS2—renal system—colon cancer	0.000582	0.0117	CbGeAlD
Etodolac—CYP2C9—digestive system—colon cancer	0.000547	0.011	CbGeAlD
Etodolac—ALB—lymph node—colon cancer	0.0005	0.0101	CbGeAlD
Etodolac—PTGS1—digestive system—colon cancer	0.000499	0.0101	CbGeAlD
Etodolac—PTGS2—lymphoid tissue—colon cancer	0.000483	0.00973	CbGeAlD
Etodolac—PTGS2—digestive system—colon cancer	0.000477	0.00961	CbGeAlD
Etodolac—PTGS1—vagina—colon cancer	0.000441	0.00888	CbGeAlD
Etodolac—PTGS2—bone marrow—colon cancer	0.00044	0.00886	CbGeAlD
Etodolac—PTGS2—vagina—colon cancer	0.000421	0.00849	CbGeAlD
Etodolac—CYP2C9—liver—colon cancer	0.000407	0.00821	CbGeAlD
Etodolac—PTGS2—liver—colon cancer	0.000356	0.00716	CbGeAlD
Etodolac—Malaise—Irinotecan—colon cancer	0.000316	0.00241	CcSEcCtD
Etodolac—Vertigo—Irinotecan—colon cancer	0.000315	0.0024	CcSEcCtD
Etodolac—Dysuria—Capecitabine—colon cancer	0.000315	0.0024	CcSEcCtD
Etodolac—Neutropenia—Capecitabine—colon cancer	0.000315	0.0024	CcSEcCtD
Etodolac—Syncope—Irinotecan—colon cancer	0.000314	0.00239	CcSEcCtD
Etodolac—Leukopenia—Irinotecan—colon cancer	0.000314	0.00239	CcSEcCtD
Etodolac—Convulsion—Vincristine—colon cancer	0.000312	0.00238	CcSEcCtD
Etodolac—Hypertension—Vincristine—colon cancer	0.000311	0.00237	CcSEcCtD
Etodolac—Anaemia—Fluorouracil—colon cancer	0.00031	0.00236	CcSEcCtD
Etodolac—Loss of consciousness—Irinotecan—colon cancer	0.000308	0.00235	CcSEcCtD
Etodolac—Dermatitis exfoliative—Methotrexate—colon cancer	0.000307	0.00234	CcSEcCtD
Etodolac—Photosensitivity reaction—Capecitabine—colon cancer	0.000307	0.00234	CcSEcCtD
Etodolac—Myalgia—Vincristine—colon cancer	0.000306	0.00233	CcSEcCtD
Etodolac—Visual disturbance—Methotrexate—colon cancer	0.000306	0.00233	CcSEcCtD
Etodolac—Hyperglycaemia—Capecitabine—colon cancer	0.000304	0.00231	CcSEcCtD
Etodolac—Hypertension—Irinotecan—colon cancer	0.000303	0.00231	CcSEcCtD
Etodolac—Pneumonia—Capecitabine—colon cancer	0.000302	0.0023	CcSEcCtD
Etodolac—Leukopenia—Fluorouracil—colon cancer	0.000301	0.00229	CcSEcCtD
Etodolac—Anaphylactoid reaction—Methotrexate—colon cancer	0.0003	0.00228	CcSEcCtD
Etodolac—Stevens-Johnson syndrome—Capecitabine—colon cancer	0.000298	0.00227	CcSEcCtD
Etodolac—Acute coronary syndrome—Capecitabine—colon cancer	0.000296	0.00225	CcSEcCtD
Etodolac—Cerebrovascular accident—Methotrexate—colon cancer	0.000296	0.00225	CcSEcCtD
Etodolac—Renal failure—Capecitabine—colon cancer	0.000295	0.00225	CcSEcCtD
Etodolac—Discomfort—Irinotecan—colon cancer	0.000295	0.00225	CcSEcCtD
Etodolac—Myocardial infarction—Capecitabine—colon cancer	0.000294	0.00224	CcSEcCtD
Etodolac—Anaphylactic shock—Vincristine—colon cancer	0.000294	0.00224	CcSEcCtD
Etodolac—Oedema—Vincristine—colon cancer	0.000294	0.00224	CcSEcCtD
Etodolac—Jaundice—Capecitabine—colon cancer	0.000293	0.00223	CcSEcCtD
Etodolac—Stomatitis—Capecitabine—colon cancer	0.000293	0.00223	CcSEcCtD
Etodolac—Infection—Vincristine—colon cancer	0.000292	0.00222	CcSEcCtD
Etodolac—Conjunctivitis—Capecitabine—colon cancer	0.000292	0.00222	CcSEcCtD
Etodolac—Convulsion—Fluorouracil—colon cancer	0.000291	0.00222	CcSEcCtD
Etodolac—Confusional state—Irinotecan—colon cancer	0.000289	0.0022	CcSEcCtD
Etodolac—Thrombocytopenia—Vincristine—colon cancer	0.000288	0.00219	CcSEcCtD
Etodolac—Haematuria—Capecitabine—colon cancer	0.000286	0.00218	CcSEcCtD
Etodolac—Anaphylactic shock—Irinotecan—colon cancer	0.000286	0.00218	CcSEcCtD
Etodolac—Oedema—Irinotecan—colon cancer	0.000286	0.00218	CcSEcCtD
Etodolac—Myalgia—Fluorouracil—colon cancer	0.000286	0.00218	CcSEcCtD
Etodolac—PTGS1—lymph node—colon cancer	0.000285	0.00574	CbGeAlD
Etodolac—Infection—Irinotecan—colon cancer	0.000284	0.00217	CcSEcCtD
Etodolac—Hyperhidrosis—Vincristine—colon cancer	0.000284	0.00216	CcSEcCtD
Etodolac—Discomfort—Fluorouracil—colon cancer	0.000282	0.00215	CcSEcCtD
Etodolac—Shock—Irinotecan—colon cancer	0.000282	0.00214	CcSEcCtD
Etodolac—Agranulocytosis—Capecitabine—colon cancer	0.00028	0.00213	CcSEcCtD
Etodolac—Thrombocytopenia—Irinotecan—colon cancer	0.00028	0.00213	CcSEcCtD
Etodolac—Anorexia—Vincristine—colon cancer	0.00028	0.00213	CcSEcCtD
Etodolac—Irritability—Methotrexate—colon cancer	0.000277	0.00211	CcSEcCtD
Etodolac—Hyperhidrosis—Irinotecan—colon cancer	0.000277	0.00211	CcSEcCtD
Etodolac—Confusional state—Fluorouracil—colon cancer	0.000276	0.0021	CcSEcCtD
Etodolac—Hypotension—Vincristine—colon cancer	0.000275	0.00209	CcSEcCtD
Etodolac—Oedema—Fluorouracil—colon cancer	0.000274	0.00209	CcSEcCtD
Etodolac—Anaphylactic shock—Fluorouracil—colon cancer	0.000274	0.00209	CcSEcCtD
Etodolac—Anorexia—Irinotecan—colon cancer	0.000273	0.00208	CcSEcCtD
Etodolac—PTGS2—lymph node—colon cancer	0.000273	0.00549	CbGeAlD
Etodolac—Infection—Fluorouracil—colon cancer	0.000272	0.00207	CcSEcCtD
Etodolac—Haemoglobin—Capecitabine—colon cancer	0.000271	0.00206	CcSEcCtD
Etodolac—Rhinitis—Capecitabine—colon cancer	0.00027	0.00206	CcSEcCtD
Etodolac—Haemorrhage—Capecitabine—colon cancer	0.00027	0.00205	CcSEcCtD
Etodolac—Hepatitis—Capecitabine—colon cancer	0.00027	0.00205	CcSEcCtD
Etodolac—Thrombocytopenia—Fluorouracil—colon cancer	0.000268	0.00204	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Vincristine—colon cancer	0.000268	0.00204	CcSEcCtD
Etodolac—Pharyngitis—Capecitabine—colon cancer	0.000268	0.00204	CcSEcCtD
Etodolac—Tachycardia—Fluorouracil—colon cancer	0.000267	0.00204	CcSEcCtD
Etodolac—Hypotension—Irinotecan—colon cancer	0.000267	0.00204	CcSEcCtD
Etodolac—Insomnia—Vincristine—colon cancer	0.000266	0.00202	CcSEcCtD
Etodolac—Paraesthesia—Vincristine—colon cancer	0.000264	0.00201	CcSEcCtD
Etodolac—Anorexia—Fluorouracil—colon cancer	0.000261	0.00199	CcSEcCtD
Etodolac—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.000261	0.00199	CcSEcCtD
Etodolac—Visual impairment—Capecitabine—colon cancer	0.00026	0.00198	CcSEcCtD
Etodolac—Insomnia—Irinotecan—colon cancer	0.000259	0.00197	CcSEcCtD
Etodolac—Paraesthesia—Irinotecan—colon cancer	0.000257	0.00196	CcSEcCtD
Etodolac—Hypotension—Fluorouracil—colon cancer	0.000256	0.00195	CcSEcCtD
Etodolac—Decreased appetite—Vincristine—colon cancer	0.000255	0.00195	CcSEcCtD
Etodolac—Dyspnoea—Irinotecan—colon cancer	0.000255	0.00194	CcSEcCtD
Etodolac—Erythema multiforme—Capecitabine—colon cancer	0.000255	0.00194	CcSEcCtD
Etodolac—Somnolence—Irinotecan—colon cancer	0.000254	0.00194	CcSEcCtD
Etodolac—Fatigue—Vincristine—colon cancer	0.000253	0.00193	CcSEcCtD
Etodolac—Dyspepsia—Irinotecan—colon cancer	0.000252	0.00192	CcSEcCtD
Etodolac—Tinnitus—Capecitabine—colon cancer	0.000251	0.00191	CcSEcCtD
Etodolac—Pain—Vincristine—colon cancer	0.000251	0.00191	CcSEcCtD
Etodolac—Constipation—Vincristine—colon cancer	0.000251	0.00191	CcSEcCtD
Etodolac—Asthma—Methotrexate—colon cancer	0.000251	0.00191	CcSEcCtD
Etodolac—Flushing—Capecitabine—colon cancer	0.00025	0.00191	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.00025	0.0019	CcSEcCtD
Etodolac—Decreased appetite—Irinotecan—colon cancer	0.000249	0.00189	CcSEcCtD
Etodolac—Eosinophilia—Methotrexate—colon cancer	0.000248	0.00189	CcSEcCtD
Etodolac—Insomnia—Fluorouracil—colon cancer	0.000248	0.00189	CcSEcCtD
Etodolac—Fatigue—Irinotecan—colon cancer	0.000247	0.00188	CcSEcCtD
Etodolac—Paraesthesia—Fluorouracil—colon cancer	0.000246	0.00187	CcSEcCtD
Etodolac—Pancreatitis—Methotrexate—colon cancer	0.000246	0.00187	CcSEcCtD
Etodolac—Constipation—Irinotecan—colon cancer	0.000245	0.00186	CcSEcCtD
Etodolac—Pain—Irinotecan—colon cancer	0.000245	0.00186	CcSEcCtD
Etodolac—Dyspnoea—Fluorouracil—colon cancer	0.000244	0.00186	CcSEcCtD
Etodolac—Somnolence—Fluorouracil—colon cancer	0.000244	0.00186	CcSEcCtD
Etodolac—Chills—Capecitabine—colon cancer	0.000242	0.00184	CcSEcCtD
Etodolac—Dyspepsia—Fluorouracil—colon cancer	0.000241	0.00184	CcSEcCtD
Etodolac—Arrhythmia—Capecitabine—colon cancer	0.000241	0.00183	CcSEcCtD
Etodolac—Abdominal discomfort—Methotrexate—colon cancer	0.00024	0.00183	CcSEcCtD
Etodolac—Gastrointestinal pain—Vincristine—colon cancer	0.00024	0.00183	CcSEcCtD
Etodolac—Decreased appetite—Fluorouracil—colon cancer	0.000238	0.00181	CcSEcCtD
Etodolac—Alopecia—Capecitabine—colon cancer	0.000238	0.00181	CcSEcCtD
Etodolac—Pancytopenia—Methotrexate—colon cancer	0.000238	0.00181	CcSEcCtD
Etodolac—Feeling abnormal—Irinotecan—colon cancer	0.000236	0.0018	CcSEcCtD
Etodolac—Dysuria—Methotrexate—colon cancer	0.000234	0.00179	CcSEcCtD
Etodolac—Neutropenia—Methotrexate—colon cancer	0.000234	0.00179	CcSEcCtD
Etodolac—Pain—Fluorouracil—colon cancer	0.000234	0.00178	CcSEcCtD
Etodolac—Gastrointestinal pain—Irinotecan—colon cancer	0.000234	0.00178	CcSEcCtD
Etodolac—Abdominal pain—Vincristine—colon cancer	0.000232	0.00177	CcSEcCtD
Etodolac—Body temperature increased—Vincristine—colon cancer	0.000232	0.00177	CcSEcCtD
Etodolac—Flatulence—Capecitabine—colon cancer	0.000231	0.00176	CcSEcCtD
Etodolac—Dysgeusia—Capecitabine—colon cancer	0.00023	0.00175	CcSEcCtD
Etodolac—Photosensitivity reaction—Methotrexate—colon cancer	0.000229	0.00174	CcSEcCtD
Etodolac—Abdominal pain—Irinotecan—colon cancer	0.000226	0.00172	CcSEcCtD
Etodolac—Body temperature increased—Irinotecan—colon cancer	0.000226	0.00172	CcSEcCtD
Etodolac—Feeling abnormal—Fluorouracil—colon cancer	0.000226	0.00172	CcSEcCtD
Etodolac—Pneumonia—Methotrexate—colon cancer	0.000225	0.00171	CcSEcCtD
Etodolac—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.000222	0.00169	CcSEcCtD
Etodolac—Vision blurred—Capecitabine—colon cancer	0.000221	0.00168	CcSEcCtD
Etodolac—Tremor—Capecitabine—colon cancer	0.00022	0.00167	CcSEcCtD
Etodolac—Renal failure—Methotrexate—colon cancer	0.00022	0.00167	CcSEcCtD
Etodolac—Stomatitis—Methotrexate—colon cancer	0.000218	0.00166	CcSEcCtD
Etodolac—Ill-defined disorder—Capecitabine—colon cancer	0.000218	0.00166	CcSEcCtD
Etodolac—Urticaria—Fluorouracil—colon cancer	0.000218	0.00166	CcSEcCtD
Etodolac—Conjunctivitis—Methotrexate—colon cancer	0.000217	0.00165	CcSEcCtD
Etodolac—Anaemia—Capecitabine—colon cancer	0.000217	0.00165	CcSEcCtD
Etodolac—Body temperature increased—Fluorouracil—colon cancer	0.000217	0.00165	CcSEcCtD
Etodolac—Hypersensitivity—Vincristine—colon cancer	0.000216	0.00165	CcSEcCtD
Etodolac—Sweating—Methotrexate—colon cancer	0.000214	0.00163	CcSEcCtD
Etodolac—Haematuria—Methotrexate—colon cancer	0.000213	0.00162	CcSEcCtD
Etodolac—Malaise—Capecitabine—colon cancer	0.000212	0.00161	CcSEcCtD
Etodolac—Vertigo—Capecitabine—colon cancer	0.000211	0.00161	CcSEcCtD
Etodolac—Hypersensitivity—Irinotecan—colon cancer	0.000211	0.00161	CcSEcCtD
Etodolac—Asthenia—Vincristine—colon cancer	0.000211	0.00161	CcSEcCtD
Etodolac—Syncope—Capecitabine—colon cancer	0.00021	0.0016	CcSEcCtD
Etodolac—Leukopenia—Capecitabine—colon cancer	0.00021	0.0016	CcSEcCtD
Etodolac—Agranulocytosis—Methotrexate—colon cancer	0.000209	0.00159	CcSEcCtD
Etodolac—Palpitations—Capecitabine—colon cancer	0.000207	0.00158	CcSEcCtD
Etodolac—Loss of consciousness—Capecitabine—colon cancer	0.000206	0.00157	CcSEcCtD
Etodolac—Asthenia—Irinotecan—colon cancer	0.000205	0.00156	CcSEcCtD
Etodolac—Hypertension—Capecitabine—colon cancer	0.000203	0.00154	CcSEcCtD
Etodolac—Hypersensitivity—Fluorouracil—colon cancer	0.000202	0.00154	CcSEcCtD
Etodolac—Haemoglobin—Methotrexate—colon cancer	0.000202	0.00154	CcSEcCtD
Etodolac—Diarrhoea—Vincristine—colon cancer	0.000201	0.00153	CcSEcCtD
Etodolac—Haemorrhage—Methotrexate—colon cancer	0.000201	0.00153	CcSEcCtD
Etodolac—Hepatitis—Methotrexate—colon cancer	0.000201	0.00153	CcSEcCtD
Etodolac—Myalgia—Capecitabine—colon cancer	0.0002	0.00152	CcSEcCtD
Etodolac—Arthralgia—Capecitabine—colon cancer	0.0002	0.00152	CcSEcCtD
Etodolac—Pharyngitis—Methotrexate—colon cancer	0.000199	0.00152	CcSEcCtD
Etodolac—Anxiety—Capecitabine—colon cancer	0.000199	0.00152	CcSEcCtD
Etodolac—Discomfort—Capecitabine—colon cancer	0.000197	0.0015	CcSEcCtD
Etodolac—Diarrhoea—Irinotecan—colon cancer	0.000196	0.00149	CcSEcCtD
Etodolac—Dry mouth—Capecitabine—colon cancer	0.000195	0.00149	CcSEcCtD
Etodolac—Dizziness—Vincristine—colon cancer	0.000194	0.00148	CcSEcCtD
Etodolac—Pruritus—Fluorouracil—colon cancer	0.000194	0.00148	CcSEcCtD
Etodolac—Visual impairment—Methotrexate—colon cancer	0.000193	0.00147	CcSEcCtD
Etodolac—Confusional state—Capecitabine—colon cancer	0.000193	0.00147	CcSEcCtD
Etodolac—Oedema—Capecitabine—colon cancer	0.000192	0.00146	CcSEcCtD
Etodolac—Infection—Capecitabine—colon cancer	0.00019	0.00145	CcSEcCtD
Etodolac—Erythema multiforme—Methotrexate—colon cancer	0.00019	0.00145	CcSEcCtD
Etodolac—Dizziness—Irinotecan—colon cancer	0.000189	0.00144	CcSEcCtD
Etodolac—Shock—Capecitabine—colon cancer	0.000188	0.00144	CcSEcCtD
Etodolac—Diarrhoea—Fluorouracil—colon cancer	0.000188	0.00143	CcSEcCtD
Etodolac—Thrombocytopenia—Capecitabine—colon cancer	0.000187	0.00143	CcSEcCtD
Etodolac—Tinnitus—Methotrexate—colon cancer	0.000187	0.00142	CcSEcCtD
Etodolac—Tachycardia—Capecitabine—colon cancer	0.000187	0.00142	CcSEcCtD
Etodolac—Vomiting—Vincristine—colon cancer	0.000187	0.00142	CcSEcCtD
Etodolac—Rash—Vincristine—colon cancer	0.000185	0.00141	CcSEcCtD
Etodolac—Hyperhidrosis—Capecitabine—colon cancer	0.000185	0.00141	CcSEcCtD
Etodolac—Dermatitis—Vincristine—colon cancer	0.000185	0.00141	CcSEcCtD
Etodolac—Headache—Vincristine—colon cancer	0.000184	0.0014	CcSEcCtD
Etodolac—Anorexia—Capecitabine—colon cancer	0.000183	0.00139	CcSEcCtD
Etodolac—Vomiting—Irinotecan—colon cancer	0.000182	0.00139	CcSEcCtD
Etodolac—Dizziness—Fluorouracil—colon cancer	0.000181	0.00138	CcSEcCtD
Etodolac—Rash—Irinotecan—colon cancer	0.00018	0.00137	CcSEcCtD
Etodolac—Dermatitis—Irinotecan—colon cancer	0.00018	0.00137	CcSEcCtD
Etodolac—Chills—Methotrexate—colon cancer	0.00018	0.00137	CcSEcCtD
Etodolac—Headache—Irinotecan—colon cancer	0.000179	0.00137	CcSEcCtD
Etodolac—Hypotension—Capecitabine—colon cancer	0.000179	0.00136	CcSEcCtD
Etodolac—Alopecia—Methotrexate—colon cancer	0.000177	0.00135	CcSEcCtD
Etodolac—Nausea—Vincristine—colon cancer	0.000175	0.00133	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000174	0.00133	CcSEcCtD
Etodolac—Vomiting—Fluorouracil—colon cancer	0.000174	0.00133	CcSEcCtD
Etodolac—Insomnia—Capecitabine—colon cancer	0.000173	0.00132	CcSEcCtD
Etodolac—Rash—Fluorouracil—colon cancer	0.000173	0.00132	CcSEcCtD
Etodolac—Dermatitis—Fluorouracil—colon cancer	0.000173	0.00131	CcSEcCtD
Etodolac—Paraesthesia—Capecitabine—colon cancer	0.000172	0.00131	CcSEcCtD
Etodolac—Headache—Fluorouracil—colon cancer	0.000172	0.00131	CcSEcCtD
Etodolac—Dysgeusia—Methotrexate—colon cancer	0.000171	0.0013	CcSEcCtD
Etodolac—Dyspnoea—Capecitabine—colon cancer	0.000171	0.0013	CcSEcCtD
Etodolac—Nausea—Irinotecan—colon cancer	0.00017	0.00129	CcSEcCtD
Etodolac—Dyspepsia—Capecitabine—colon cancer	0.000169	0.00128	CcSEcCtD
Etodolac—Decreased appetite—Capecitabine—colon cancer	0.000166	0.00127	CcSEcCtD
Etodolac—Fatigue—Capecitabine—colon cancer	0.000165	0.00126	CcSEcCtD
Etodolac—Vision blurred—Methotrexate—colon cancer	0.000165	0.00125	CcSEcCtD
Etodolac—Pain—Capecitabine—colon cancer	0.000164	0.00125	CcSEcCtD
Etodolac—Constipation—Capecitabine—colon cancer	0.000164	0.00125	CcSEcCtD
Etodolac—Nausea—Fluorouracil—colon cancer	0.000163	0.00124	CcSEcCtD
Etodolac—Ill-defined disorder—Methotrexate—colon cancer	0.000162	0.00123	CcSEcCtD
Etodolac—Anaemia—Methotrexate—colon cancer	0.000161	0.00123	CcSEcCtD
Etodolac—Feeling abnormal—Capecitabine—colon cancer	0.000158	0.0012	CcSEcCtD
Etodolac—Malaise—Methotrexate—colon cancer	0.000158	0.0012	CcSEcCtD
Etodolac—Vertigo—Methotrexate—colon cancer	0.000157	0.0012	CcSEcCtD
Etodolac—Gastrointestinal pain—Capecitabine—colon cancer	0.000157	0.00119	CcSEcCtD
Etodolac—Leukopenia—Methotrexate—colon cancer	0.000156	0.00119	CcSEcCtD
Etodolac—Urticaria—Capecitabine—colon cancer	0.000152	0.00116	CcSEcCtD
Etodolac—Abdominal pain—Capecitabine—colon cancer	0.000151	0.00115	CcSEcCtD
Etodolac—Body temperature increased—Capecitabine—colon cancer	0.000151	0.00115	CcSEcCtD
Etodolac—Convulsion—Methotrexate—colon cancer	0.000151	0.00115	CcSEcCtD
Etodolac—Arthralgia—Methotrexate—colon cancer	0.000149	0.00113	CcSEcCtD
Etodolac—Myalgia—Methotrexate—colon cancer	0.000149	0.00113	CcSEcCtD
Etodolac—Discomfort—Methotrexate—colon cancer	0.000147	0.00112	CcSEcCtD
Etodolac—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000146	0.00296	CbGpPWpGaD
Etodolac—Confusional state—Methotrexate—colon cancer	0.000144	0.00109	CcSEcCtD
Etodolac—UGT1A9—Metabolism—CA7—colon cancer	0.000143	0.00289	CbGpPWpGaD
Etodolac—Anaphylactic shock—Methotrexate—colon cancer	0.000143	0.00109	CcSEcCtD
Etodolac—Infection—Methotrexate—colon cancer	0.000142	0.00108	CcSEcCtD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—ABCB1—colon cancer	0.000141	0.00286	CbGpPWpGaD
Etodolac—Hypersensitivity—Capecitabine—colon cancer	0.000141	0.00107	CcSEcCtD
Etodolac—RXRA—a6b1 and a6b4 Integrin signaling—HRAS—colon cancer	0.00014	0.00283	CbGpPWpGaD
Etodolac—Thrombocytopenia—Methotrexate—colon cancer	0.00014	0.00106	CcSEcCtD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	0.000139	0.00281	CbGpPWpGaD
Etodolac—Hyperhidrosis—Methotrexate—colon cancer	0.000138	0.00105	CcSEcCtD
Etodolac—Asthenia—Capecitabine—colon cancer	0.000137	0.00105	CcSEcCtD
Etodolac—Anorexia—Methotrexate—colon cancer	0.000136	0.00104	CcSEcCtD
Etodolac—Pruritus—Capecitabine—colon cancer	0.000135	0.00103	CcSEcCtD
Etodolac—RXRA—Adipogenesis—PPARG—colon cancer	0.000134	0.00271	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	0.000134	0.00271	CbGpPWpGaD
Etodolac—Hypotension—Methotrexate—colon cancer	0.000133	0.00101	CcSEcCtD
Etodolac—UGT1A9—PPARA activates gene expression—PPARG—colon cancer	0.000133	0.0027	CbGpPWpGaD
Etodolac—RXRA—Transcriptional regulation of white adipocyte differentiation—EP300—colon cancer	0.000133	0.00269	CbGpPWpGaD
Etodolac—Diarrhoea—Capecitabine—colon cancer	0.000131	0.000998	CcSEcCtD
Etodolac—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—colon cancer	0.00013	0.00264	CbGpPWpGaD
Etodolac—Musculoskeletal discomfort—Methotrexate—colon cancer	0.00013	0.000989	CcSEcCtD
Etodolac—Insomnia—Methotrexate—colon cancer	0.000129	0.000982	CcSEcCtD
Etodolac—Paraesthesia—Methotrexate—colon cancer	0.000128	0.000975	CcSEcCtD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	0.000128	0.00258	CbGpPWpGaD
Etodolac—Dyspnoea—Methotrexate—colon cancer	0.000127	0.000968	CcSEcCtD
Etodolac—Somnolence—Methotrexate—colon cancer	0.000127	0.000965	CcSEcCtD
Etodolac—Dizziness—Capecitabine—colon cancer	0.000127	0.000965	CcSEcCtD
Etodolac—RXRA—Developmental Biology—DCC—colon cancer	0.000126	0.00255	CbGpPWpGaD
Etodolac—Dyspepsia—Methotrexate—colon cancer	0.000125	0.000956	CcSEcCtD
Etodolac—UGT1A3—Metabolism—CHST5—colon cancer	0.000125	0.00254	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—ODC1—colon cancer	0.000125	0.00254	CbGpPWpGaD
Etodolac—Decreased appetite—Methotrexate—colon cancer	0.000124	0.000944	CcSEcCtD
Etodolac—RXRA—a6b1 and a6b4 Integrin signaling—AKT1—colon cancer	0.000123	0.0025	CbGpPWpGaD
Etodolac—Fatigue—Methotrexate—colon cancer	0.000123	0.000936	CcSEcCtD
Etodolac—Pain—Methotrexate—colon cancer	0.000122	0.000929	CcSEcCtD
Etodolac—Vomiting—Capecitabine—colon cancer	0.000122	0.000927	CcSEcCtD
Etodolac—Rash—Capecitabine—colon cancer	0.000121	0.00092	CcSEcCtD
Etodolac—Dermatitis—Capecitabine—colon cancer	0.000121	0.000919	CcSEcCtD
Etodolac—Headache—Capecitabine—colon cancer	0.00012	0.000914	CcSEcCtD
Etodolac—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—colon cancer	0.000119	0.00241	CbGpPWpGaD
Etodolac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—colon cancer	0.000118	0.00239	CbGpPWpGaD
Etodolac—Feeling abnormal—Methotrexate—colon cancer	0.000117	0.000895	CcSEcCtD
Etodolac—Gastrointestinal pain—Methotrexate—colon cancer	0.000117	0.000888	CcSEcCtD
Etodolac—PTGS1—Metabolism—CA7—colon cancer	0.000116	0.00236	CbGpPWpGaD
Etodolac—RXRA—Transcriptional regulation of white adipocyte differentiation—TGFB1—colon cancer	0.000116	0.00234	CbGpPWpGaD
Etodolac—Nausea—Capecitabine—colon cancer	0.000114	0.000866	CcSEcCtD
Etodolac—Urticaria—Methotrexate—colon cancer	0.000113	0.000863	CcSEcCtD
Etodolac—PTGS2—Aryl Hydrocarbon Receptor—EP300—colon cancer	0.000113	0.00229	CbGpPWpGaD
Etodolac—Body temperature increased—Methotrexate—colon cancer	0.000113	0.000858	CcSEcCtD
Etodolac—Abdominal pain—Methotrexate—colon cancer	0.000113	0.000858	CcSEcCtD
Etodolac—RXRA—Generic Transcription Pathway—HNF4A—colon cancer	0.000112	0.00228	CbGpPWpGaD
Etodolac—PTGS2—Aryl Hydrocarbon Receptor—SRC—colon cancer	0.00011	0.00223	CbGpPWpGaD
Etodolac—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—colon cancer	0.000107	0.00217	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—ODC1—colon cancer	0.000107	0.00216	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—CHST5—colon cancer	0.000107	0.00216	CbGpPWpGaD
Etodolac—PTGS2—Aryl Hydrocarbon Receptor—NRAS—colon cancer	0.000106	0.00214	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—HNF4A—colon cancer	0.000106	0.00214	CbGpPWpGaD
Etodolac—Hypersensitivity—Methotrexate—colon cancer	0.000105	0.0008	CcSEcCtD
Etodolac—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—colon cancer	0.000103	0.00209	CbGpPWpGaD
Etodolac—Asthenia—Methotrexate—colon cancer	0.000102	0.000779	CcSEcCtD
Etodolac—PTGS1—Selenium Micronutrient Network—PTGS2—colon cancer	0.000102	0.00207	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	0.000102	0.00207	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—APC—colon cancer	0.000102	0.00206	CbGpPWpGaD
Etodolac—Pruritus—Methotrexate—colon cancer	0.000101	0.000768	CcSEcCtD
Etodolac—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—colon cancer	0.000101	0.00204	CbGpPWpGaD
Etodolac—RXRA—PPARA activates gene expression—EP300—colon cancer	0.0001	0.00202	CbGpPWpGaD
Etodolac—RXRA—Metabolism—ODC1—colon cancer	9.94e-05	0.00201	CbGpPWpGaD
Etodolac—RXRA—Metabolism—CHST5—colon cancer	9.94e-05	0.00201	CbGpPWpGaD
Etodolac—PTGS2—Aryl Hydrocarbon Receptor—MYC—colon cancer	9.86e-05	0.002	CbGpPWpGaD
Etodolac—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—colon cancer	9.78e-05	0.00198	CbGpPWpGaD
Etodolac—Diarrhoea—Methotrexate—colon cancer	9.75e-05	0.000743	CcSEcCtD
Etodolac—PTGS2—Aryl Hydrocarbon Receptor—EGFR—colon cancer	9.65e-05	0.00195	CbGpPWpGaD
Etodolac—Dizziness—Methotrexate—colon cancer	9.43e-05	0.000718	CcSEcCtD
Etodolac—RXRA—Adipogenesis—CTNNB1—colon cancer	9.41e-05	0.00191	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—CA7—colon cancer	9.25e-05	0.00187	CbGpPWpGaD
Etodolac—RXRA—Adipogenesis—CDKN1A—colon cancer	9.19e-05	0.00186	CbGpPWpGaD
Etodolac—PTGS2—Aryl Hydrocarbon Receptor—KRAS—colon cancer	9.11e-05	0.00185	CbGpPWpGaD
Etodolac—Vomiting—Methotrexate—colon cancer	9.06e-05	0.00069	CcSEcCtD
Etodolac—Rash—Methotrexate—colon cancer	8.99e-05	0.000685	CcSEcCtD
Etodolac—Dermatitis—Methotrexate—colon cancer	8.98e-05	0.000684	CcSEcCtD
Etodolac—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—colon cancer	8.98e-05	0.00182	CbGpPWpGaD
Etodolac—Headache—Methotrexate—colon cancer	8.93e-05	0.00068	CcSEcCtD
Etodolac—UGT1A3—NRF2 pathway—TGFB1—colon cancer	8.73e-05	0.00177	CbGpPWpGaD
Etodolac—UGT1A9—PPARA activates gene expression—EP300—colon cancer	8.71e-05	0.00176	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—ODC1—colon cancer	8.66e-05	0.00175	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—CHST5—colon cancer	8.66e-05	0.00175	CbGpPWpGaD
Etodolac—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—colon cancer	8.52e-05	0.00173	CbGpPWpGaD
Etodolac—Nausea—Methotrexate—colon cancer	8.47e-05	0.000645	CcSEcCtD
Etodolac—CYP2C9—Arachidonic acid metabolism—PTGS2—colon cancer	8.43e-05	0.00171	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—colon cancer	7.96e-05	0.00161	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	7.82e-05	0.00158	CbGpPWpGaD
Etodolac—PTGS2—Aryl Hydrocarbon Receptor—HRAS—colon cancer	7.75e-05	0.00157	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	7.73e-05	0.00157	CbGpPWpGaD
Etodolac—RXRA—Adipogenesis—TGFB1—colon cancer	7.6e-05	0.00154	CbGpPWpGaD
Etodolac—PTGS2—C-MYB transcription factor network—CCND1—colon cancer	7.6e-05	0.00154	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	7.53e-05	0.00153	CbGpPWpGaD
Etodolac—ALB—Metabolism—CA7—colon cancer	7.48e-05	0.00152	CbGpPWpGaD
Etodolac—UGT2B7—NRF2 pathway—TGFB1—colon cancer	7.43e-05	0.0015	CbGpPWpGaD
Etodolac—PTGS2—C-MYB transcription factor network—CDKN1A—colon cancer	7.35e-05	0.00149	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	7.17e-05	0.00145	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—ODC1—colon cancer	7.06e-05	0.00143	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—CHST5—colon cancer	7.06e-05	0.00143	CbGpPWpGaD
Etodolac—PTGS2—C-MYB transcription factor network—EP300—colon cancer	6.99e-05	0.00142	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	6.98e-05	0.00141	CbGpPWpGaD
Etodolac—RXRA—NRF2 pathway—TGFB1—colon cancer	6.93e-05	0.0014	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	6.92e-05	0.0014	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	6.76e-05	0.00137	CbGpPWpGaD
Etodolac—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—colon cancer	6.74e-05	0.00137	CbGpPWpGaD
Etodolac—PTGS2—Disease—CHST5—colon cancer	6.69e-05	0.00136	CbGpPWpGaD
Etodolac—PTGS2—Disease—LGR5—colon cancer	6.69e-05	0.00136	CbGpPWpGaD
Etodolac—ALB—Selenium Micronutrient Network—PTGS2—colon cancer	6.55e-05	0.00133	CbGpPWpGaD
Etodolac—PTGS2—C-MYB transcription factor network—NRAS—colon cancer	6.54e-05	0.00132	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	6.43e-05	0.0013	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	6.25e-05	0.00127	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—CA7—colon cancer	6.12e-05	0.00124	CbGpPWpGaD
Etodolac—PTGS2—C-MYB transcription factor network—MYC—colon cancer	6.09e-05	0.00123	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	6.09e-05	0.00123	CbGpPWpGaD
Etodolac—UGT1A9—NRF2 pathway—TGFB1—colon cancer	6.04e-05	0.00122	CbGpPWpGaD
Etodolac—PTGS2—Spinal Cord Injury—CASP3—colon cancer	5.95e-05	0.0012	CbGpPWpGaD
Etodolac—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—colon cancer	5.87e-05	0.00119	CbGpPWpGaD
Etodolac—PTGS2—Spinal Cord Injury—CCND1—colon cancer	5.79e-05	0.00117	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—APC—colon cancer	5.74e-05	0.00116	CbGpPWpGaD
Etodolac—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—colon cancer	5.73e-05	0.00116	CbGpPWpGaD
Etodolac—PTGS2—C-MYB transcription factor network—KRAS—colon cancer	5.63e-05	0.00114	CbGpPWpGaD
Etodolac—RXRA—Transmembrane transport of small molecules—ABCB1—colon cancer	5.61e-05	0.00114	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—ODC1—colon cancer	5.6e-05	0.00113	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—CHST5—colon cancer	5.6e-05	0.00113	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	5.6e-05	0.00113	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	5.59e-05	0.00113	CbGpPWpGaD
Etodolac—ALB—Platelet degranulation—VEGFA—colon cancer	5.57e-05	0.00113	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	5.48e-05	0.00111	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—HNF4A—colon cancer	5.41e-05	0.0011	CbGpPWpGaD
Etodolac—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—colon cancer	5.31e-05	0.00107	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	5.18e-05	0.00105	CbGpPWpGaD
Etodolac—ALB—Platelet degranulation—TGFB1—colon cancer	5.11e-05	0.00104	CbGpPWpGaD
Etodolac—SLC22A6—Transmembrane transport of small molecules—ABCB1—colon cancer	4.92e-05	0.000997	CbGpPWpGaD
Etodolac—ALB—Folate Metabolism—TP53—colon cancer	4.91e-05	0.000994	CbGpPWpGaD
Etodolac—RXRA—Generic Transcription Pathway—PPARG—colon cancer	4.88e-05	0.000989	CbGpPWpGaD
Etodolac—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—colon cancer	4.87e-05	0.000987	CbGpPWpGaD
Etodolac—PTGS2—Disease—AXIN2—colon cancer	4.81e-05	0.000974	CbGpPWpGaD
Etodolac—PTGS2—C-MYB transcription factor network—HRAS—colon cancer	4.79e-05	0.000969	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	4.76e-05	0.000963	CbGpPWpGaD
Etodolac—PTGS2—Spinal Cord Injury—MYC—colon cancer	4.64e-05	0.00094	CbGpPWpGaD
Etodolac—PTGS2—Spinal Cord Injury—TGFB1—colon cancer	4.63e-05	0.000938	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	4.6e-05	0.000932	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—PPARG—colon cancer	4.59e-05	0.000931	CbGpPWpGaD
Etodolac—PTGS2—Spinal Cord Injury—EGFR—colon cancer	4.54e-05	0.00092	CbGpPWpGaD
Etodolac—ALB—Metabolism—ODC1—colon cancer	4.53e-05	0.000918	CbGpPWpGaD
Etodolac—ALB—Metabolism—CHST5—colon cancer	4.53e-05	0.000918	CbGpPWpGaD
Etodolac—RXRA—Metabolism of lipids and lipoproteins—PPARG—colon cancer	4.1e-05	0.000831	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	4.04e-05	0.000819	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	3.94e-05	0.000797	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	3.9e-05	0.00079	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	3.88e-05	0.000787	CbGpPWpGaD
Etodolac—PTGS2—Spinal Cord Injury—TP53—colon cancer	3.81e-05	0.000772	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	3.81e-05	0.000771	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—CHST5—colon cancer	3.71e-05	0.000752	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—ODC1—colon cancer	3.71e-05	0.000752	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	3.62e-05	0.000734	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—colon cancer	3.57e-05	0.000724	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	3.52e-05	0.000714	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	3.43e-05	0.000695	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—ABCB1—colon cancer	3.31e-05	0.000671	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—TYMS—colon cancer	3.25e-05	0.000659	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—CTNNB1—colon cancer	3.23e-05	0.000655	CbGpPWpGaD
Etodolac—RXRA—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	3.23e-05	0.000654	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	3.16e-05	0.00064	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	3.15e-05	0.000638	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	3.09e-05	0.000626	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—EP300—colon cancer	3.01e-05	0.000609	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—SRC—colon cancer	2.92e-05	0.000592	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	2.92e-05	0.000591	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	2.91e-05	0.00059	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—VEGFA—colon cancer	2.85e-05	0.000577	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—ABCB1—colon cancer	2.82e-05	0.00057	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—NRAS—colon cancer	2.81e-05	0.00057	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	2.81e-05	0.00057	CbGpPWpGaD
Etodolac—RXRA—Generic Transcription Pathway—MYC—colon cancer	2.78e-05	0.000564	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—TYMS—colon cancer	2.77e-05	0.00056	CbGpPWpGaD
Etodolac—RXRA—Metabolism of lipids and lipoproteins—EP300—colon cancer	2.68e-05	0.000544	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	2.68e-05	0.000543	CbGpPWpGaD
Etodolac—RXRA—Metabolism—ABCB1—colon cancer	2.63e-05	0.000532	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—TGFB1—colon cancer	2.61e-05	0.000529	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	2.59e-05	0.000525	CbGpPWpGaD
Etodolac—RXRA—Metabolism—TYMS—colon cancer	2.58e-05	0.000522	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—EGFR—colon cancer	2.56e-05	0.000519	CbGpPWpGaD
Etodolac—ALB—Transmembrane transport of small molecules—ABCB1—colon cancer	2.56e-05	0.000518	CbGpPWpGaD
Etodolac—ALB—Platelet activation, signaling and aggregation—SRC—colon cancer	2.54e-05	0.000514	CbGpPWpGaD
Etodolac—ALB—Platelet activation, signaling and aggregation—VEGFA—colon cancer	2.47e-05	0.000501	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—KRAS—colon cancer	2.42e-05	0.00049	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—PPARG—colon cancer	2.35e-05	0.000476	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—EP300—colon cancer	2.34e-05	0.000474	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	2.31e-05	0.000469	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—PPARG—colon cancer	2.3e-05	0.000467	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	2.29e-05	0.000464	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—ABCB1—colon cancer	2.29e-05	0.000463	CbGpPWpGaD
Etodolac—ALB—Platelet activation, signaling and aggregation—TGFB1—colon cancer	2.27e-05	0.000459	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—TYMS—colon cancer	2.25e-05	0.000455	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	2.19e-05	0.000444	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—HRAS—colon cancer	2.06e-05	0.000417	CbGpPWpGaD
Etodolac—RXRA—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.99e-05	0.000402	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—PPARG—colon cancer	1.96e-05	0.000397	CbGpPWpGaD
Etodolac—ALB—Platelet activation, signaling and aggregation—PIK3CA—colon cancer	1.93e-05	0.000391	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.91e-05	0.000386	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.87e-05	0.000379	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—ABCB1—colon cancer	1.87e-05	0.000378	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—TYMS—colon cancer	1.83e-05	0.000371	CbGpPWpGaD
Etodolac—RXRA—Metabolism—PPARG—colon cancer	1.83e-05	0.00037	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—AKT1—colon cancer	1.82e-05	0.000368	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—PTGS2—colon cancer	1.81e-05	0.000367	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.73e-05	0.00035	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—PPARG—colon cancer	1.59e-05	0.000322	CbGpPWpGaD
Etodolac—ALB—Platelet activation, signaling and aggregation—AKT1—colon cancer	1.58e-05	0.000319	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—PTGS2—colon cancer	1.54e-05	0.000312	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.53e-05	0.00031	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.51e-05	0.000307	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—EP300—colon cancer	1.51e-05	0.000305	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—ABCB1—colon cancer	1.48e-05	0.0003	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.47e-05	0.000298	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—TYMS—colon cancer	1.45e-05	0.000295	CbGpPWpGaD
Etodolac—RXRA—Metabolism—PTGS2—colon cancer	1.44e-05	0.000291	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.41e-05	0.000286	CbGpPWpGaD
Etodolac—PTGS2—Disease—FGFR3—colon cancer	1.39e-05	0.000281	CbGpPWpGaD
Etodolac—ALB—Hemostasis—EP300—colon cancer	1.34e-05	0.000272	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—MYC—colon cancer	1.34e-05	0.000271	CbGpPWpGaD
Etodolac—ALB—Hemostasis—SRC—colon cancer	1.31e-05	0.000265	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PPARG—colon cancer	1.3e-05	0.000263	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—EP300—colon cancer	1.28e-05	0.00026	CbGpPWpGaD
Etodolac—PTGS2—Disease—APC—colon cancer	1.27e-05	0.000258	CbGpPWpGaD
Etodolac—ALB—Hemostasis—VEGFA—colon cancer	1.27e-05	0.000258	CbGpPWpGaD
Etodolac—ALB—Hemostasis—NRAS—colon cancer	1.26e-05	0.000255	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—PTGS2—colon cancer	1.25e-05	0.000254	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.22e-05	0.000248	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.2e-05	0.000244	CbGpPWpGaD
Etodolac—PTGS2—Disease—BRAF—colon cancer	1.2e-05	0.000243	CbGpPWpGaD
Etodolac—ALB—Metabolism—ABCB1—colon cancer	1.2e-05	0.000243	CbGpPWpGaD
Etodolac—RXRA—Metabolism—EP300—colon cancer	1.2e-05	0.000242	CbGpPWpGaD
Etodolac—ALB—Metabolism—TYMS—colon cancer	1.18e-05	0.000238	CbGpPWpGaD
Etodolac—ALB—Hemostasis—TGFB1—colon cancer	1.17e-05	0.000237	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.12e-05	0.000227	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—PIK3CA—colon cancer	1.11e-05	0.000226	CbGpPWpGaD
Etodolac—ALB—Hemostasis—KRAS—colon cancer	1.08e-05	0.000219	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—EP300—colon cancer	1.04e-05	0.000211	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—PPARG—colon cancer	1.03e-05	0.000209	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PTGS2—colon cancer	1.02e-05	0.000207	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—EP300—colon cancer	1e-05	0.000203	CbGpPWpGaD
Etodolac—ALB—Hemostasis—PIK3CA—colon cancer	9.95e-06	0.000202	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—ABCB1—colon cancer	9.8e-06	0.000199	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—TYMS—colon cancer	9.63e-06	0.000195	CbGpPWpGaD
Etodolac—ALB—Hemostasis—TP53—colon cancer	9.62e-06	0.000195	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—PIK3CA—colon cancer	9.48e-06	0.000192	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—AKT1—colon cancer	9.29e-06	0.000188	CbGpPWpGaD
Etodolac—ALB—Hemostasis—HRAS—colon cancer	9.2e-06	0.000186	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—AKT1—colon cancer	9.11e-06	0.000184	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	9.06e-06	0.000183	CbGpPWpGaD
Etodolac—RXRA—Metabolism—PIK3CA—colon cancer	8.84e-06	0.000179	CbGpPWpGaD
Etodolac—PTGS2—Disease—CTNNB1—colon cancer	8.66e-06	0.000175	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—EP300—colon cancer	8.49e-06	0.000172	CbGpPWpGaD
Etodolac—PTGS2—Disease—CDKN1A—colon cancer	8.46e-06	0.000171	CbGpPWpGaD
Etodolac—ALB—Metabolism—PPARG—colon cancer	8.33e-06	0.000169	CbGpPWpGaD
Etodolac—ALB—Hemostasis—AKT1—colon cancer	8.13e-06	0.000165	CbGpPWpGaD
Etodolac—PTGS2—Disease—EP300—colon cancer	8.05e-06	0.000163	CbGpPWpGaD
Etodolac—PTGS2—Disease—SRC—colon cancer	7.83e-06	0.000159	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—AKT1—colon cancer	7.74e-06	0.000157	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—PIK3CA—colon cancer	7.7e-06	0.000156	CbGpPWpGaD
Etodolac—PTGS2—Disease—NRAS—colon cancer	7.53e-06	0.000152	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	7.41e-06	0.00015	CbGpPWpGaD
Etodolac—RXRA—Metabolism—AKT1—colon cancer	7.22e-06	0.000146	CbGpPWpGaD
Etodolac—PTGS2—Disease—MYC—colon cancer	7.01e-06	0.000142	CbGpPWpGaD
Etodolac—PTGS2—Disease—TGFB1—colon cancer	7e-06	0.000142	CbGpPWpGaD
Etodolac—PTGS2—Disease—EGFR—colon cancer	6.86e-06	0.000139	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PPARG—colon cancer	6.82e-06	0.000138	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—EP300—colon cancer	6.74e-06	0.000137	CbGpPWpGaD
Etodolac—ALB—Metabolism—PTGS2—colon cancer	6.56e-06	0.000133	CbGpPWpGaD
Etodolac—PTGS2—Disease—KRAS—colon cancer	6.48e-06	0.000131	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—AKT1—colon cancer	6.29e-06	0.000127	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PIK3CA—colon cancer	6.28e-06	0.000127	CbGpPWpGaD
Etodolac—PTGS2—Disease—PIK3CA—colon cancer	5.95e-06	0.000121	CbGpPWpGaD
Etodolac—PTGS2—Disease—HRAS—colon cancer	5.51e-06	0.000112	CbGpPWpGaD
Etodolac—ALB—Metabolism—EP300—colon cancer	5.45e-06	0.00011	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PTGS2—colon cancer	5.37e-06	0.000109	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—AKT1—colon cancer	5.13e-06	0.000104	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—PIK3CA—colon cancer	4.99e-06	0.000101	CbGpPWpGaD
Etodolac—PTGS2—Disease—AKT1—colon cancer	4.86e-06	9.85e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—EP300—colon cancer	4.46e-06	9.04e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—AKT1—colon cancer	4.07e-06	8.25e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—PIK3CA—colon cancer	4.03e-06	8.17e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PIK3CA—colon cancer	3.3e-06	6.69e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—AKT1—colon cancer	3.29e-06	6.67e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—AKT1—colon cancer	2.7e-06	5.46e-05	CbGpPWpGaD
